Clinical trial
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children…
NCT00162227 · Bristol-Myers Squibb, Industry · No longer available
Key facts
| NCT number | NCT00162227 |
|---|---|
| Title | An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection |
| Official title | US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266) |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | No longer available |
| Study type | Expanded Access |
| Conditions | HIV Infection |
| Intervention type | Drug |
| Interventions | Efavirenz |
| Start date | Sep 1, 2000 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Sep 13, 2005 |
| Last update posted | Jan 9, 2014 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: